Evidence map›Paper›PMID 40116738›Full record

GuidelineEuropean heart journal2025

2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models.

Emanuele Di Angelantonio, Lisa Pennells, Magdy Abdelhamid, Victor Aboyans, Riccardo Asteggiano, Jelena Čelutkienė, Diederick E Grobbee, Bernard Iung, Peter Jüni, John William McEvoy and 5 more

Abstract readPractice Guideline
In one paragraph

Guideline in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Emanuele Di AngelantonioBritish Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB, UK.ORCID 0000-0001-8776-6719
Lisa PennellsBritish Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB, UK.ORCID 0000-0002-8594-3061
Magdy AbdelhamidDepartment of Cardiovascular Medicine at the Faculty of Medicine, Kasr El Ainy, Cairo University, Cairo, Egypt.ORCID 0000-0002-6701-7072
Victor AboyansDepartment of Cardiology at the Dupuytren University Hospital, Limoges, France.ORCID 0000-0002-0322-9818
Riccardo AsteggianoFaculty of Medicine, Insubria University, Varese, and Laboratorio Analisi e Ricerca Clinica, Turin, Italy.ORCID 0000-0002-2273-7228
Jelena ČelutkienėClinic of Cardiac and Vascular Diseases, Vilnius University, Vilnius, Lithuania.ORCID 0000-0003-3562-9274
Diederick E GrobbeeUniversity Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.ORCID 0000-0003-4472-4468
Bernard IungHospital Bichat-Claude Bernard, Université de Paris, Paris, France.
Peter JüniClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-5985-0670
John William McEvoyDepartment of Cardiology, University of Galway, School of Medicine, Galway, Ireland.ORCID 0000-0001-6530-5479
Amina RakishevaCardiology Department, City Cardiology Center, Almaty, Kazakhstan.ORCID 0000-0001-9842-962X
Xavier RosselloCardiology Department, Hospital Universitari Son Espases, Health Research Institute of the Balearic Islands (IdiSBa), Palma de Mallorca, Spain.ORCID 0000-0001-6783-8463
Frank L J VisserenDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.ORCID 0000-0003-3951-5223
Colin BaigentClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-4856-7420
Eva B PrescottDepartment of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark.ORCID 0000-0002-4134-0349

Funding

British Heart FoundationCambridge BHF Centre of Research ExcellenceChief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development DivisionNIHR Cambridge Biomedical Research CentrePublic Health AgencyUK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social CareWellcome Trust
6 · The paper itself

Abstract

The level of evidence (LOE) grading system for European Society of Cardiology (ESC) Clinical Practice Guidelines (CPG) classifies the quality of the evidence supporting a recommendation. However, the current taxonomy does not fully consider the optimal study design necessary to establish evidence for different types of recommendations in ESC guidelines. Therefore, two separate task forces of clinical and methodological experts were appointed by the CPG Committee, with the first tasked with updating the LOE grading system for therapy and prevention and the second responsible for developing a LOE grading system for diagnosis and prediction. This report from the second of these Task Forces develops a new system for diagnostic tests and prediction models which maintains the three-level grading structure to classify the quality of the evidence but introduces new definitions specific for diagnosis and prediction. For diagnostic tests, LOE A represents conclusive evidence of adequate diagnostic ability from at least two high-quality studies. Level of evidence B represents suggestive evidence from one high-quality or at least two moderate-quality studies. Level of evidence C represents preliminary evidence not classified as A or B, including evidence from less than two moderate-quality studies, or from expert consensus. For prediction models, LOE A represents conclusive evidence of adequate predictive ability from at least one high-quality derivation and two or more external validation studies of at least moderate quality. Level of evidence B represents suggestive evidence in one or more derivation studies and one or more external validation studies of at least moderate quality. Level of evidence C represents preliminary evidence not classified as A or B, including evidence from a derivation study of at least moderate quality, but with low quality or no external validation, or a derivation study of low quality.

Indexed as

CardiologyDiagnostic Tests, RoutineEvidence-Based MedicineEuropeHumansSocieties, MedicalCardiovascular diseaseClinical Practice GuidelinesDiagnostic abilityDiagnostic testsEuropean Society of CardiologyEvidence gradingPrediction modelsPredictive abilityStudy quality

Identifiers

PMID40116738
PMCPMC12093145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.